Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investor Update:

NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is continuing its investigation of claims on behalf of...

Related Keywords

New York ,United States ,California ,New Jersey ,Oakland ,Chicago ,Illinois ,Laurenced King ,Los Angeles ,Jeffreyp Campisi ,Kaplan Fox ,Y Mabs Therapeutics Inc ,Drug Administration ,Kaplan Fox Kilsheimer ,Y Mabs Therapeutics ,Biologics License Application ,Oncologic Drugs Advisory Committee Meeting ,Attorney Advertising ,Kaplan Fox Amp Kilsheimer Llp ,Smab ,Y Mabs ,For Investing ,R Wallstreetbets ,R Wsb ,Sda License ,Mabs ,Mabs Investors ,Lass Action ,